FP
BPMC

Foundry Partners’s Blueprint Medicines BPMC Stock Holding History

Foundry Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,002
Closed -$486K – 382
2021
Q1 		$486K Sell
5,002
-2,299
-31% -$230K 0.02% 386
2020
Q4 		$819K Sell
7,301
-34
-0.5% -$3.58K 0.03% 339
2020
Q3 		$680K Sell
7,335
-7,853
-52% -$605K 0.03% 338
2020
Q2 		$1.19M Sell
15,188
-578
-4% -$39.1K 0.06% 292
2020
Q1 		$922K Hold
15,766
– – 0.05% 300
2019
Q4 		$1.26M Sell
15,766
-1,226
-7% -$91.8K 0.05% 306
2019
Q3 		$1.25M Buy
16,992
+812
+5% +$70.2K 0.05% 302
2019
Q2 		$1.53M Sell
16,180
-47
-0.3% -$3.88K 0.06% 291
2019
Q1 		$1.3M Buy
16,227
+1,349
+9% +$99.7K 0.05% 305
2018
Q4 		$802K Sell
14,878
-25
-0.2% -$1.52K 0.04% 325
2018
Q3 		$1.16M Sell
14,903
-23
-0.2% -$1.6K 0.04% 318
2018
Q2 		$948K Sell
14,926
-976
-6% -$77.7K 0.04% 319
2018
Q1 		$1.46M Sell
15,902
-40
-0.3% -$3.45K 0.06% 302
2017
Q4 		$1.2M Sell
15,942
-20,638
-56% -$1.45M 0.05% 305
2017
Q3 		$2.55M Sell
36,580
-107
-0.3% -$5.72K 0.1% 285
2017
Q2 		$1.86M Sell
36,687
-844
-2% -$35.8K 0.08% 312
2017
Q1 		$1.5M Sell
37,531
-85
-0.2% -$3.04K 0.06% 327
2016
Q4 		$1.05M Buy
+37,616
New +$1.13M 0.05% 343

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Foundry Partners's BPMC Position: Q2 2021 in Review

Foundry Partners sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 5,002 shares — an estimated $486K sold.

Foundry Partners first reported a position in BPMC in Q4 2016 and held it in 18 quarters. The position peaked at $2.55M in Q3 2017. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

  • Foundry Partners reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
  • Foundry Partners sold 5,002 Blueprint Medicines shares in Q2 2021, an estimated $486K.
  • Foundry Partners first reported a position in Blueprint Medicines in Q4 2016 and held it in 18 quarters.
  • Foundry Partners's Blueprint Medicines position peaked at $2.55M in Q3 2017.
  • 281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Foundry Partners's 13F filing for Q2 2021, filed 23 Jul 2021.